NATALIA MYSH: Open Payments
NPI 1679938237 · NAPLES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,658 in 14 payments from 10 companies in 2025. Trend: 2023 $362 · 2024 $894 · 2025 $1,658
Food & beverage: $1,658
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 2 | $292 |
| Madrigal Pharmaceuticals | 2 | $280 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $227 |
| Lilly USA, LLC | 2 | $148 |
| Astellas Pharma US Inc | 1 | $140 |
| AstraZeneca Pharmaceuticals LP | 1 | $122 |
| ABBVIE INC. | 1 | $120 |
| Biogen, Inc. | 1 | $120 |
| Alnylam Pharmaceuticals Inc. | 1 | $119 |
| Boston Scientific Corporation | 1 | $89 |
Products named: TREMFYA, REZDIFFRA, CAPLYTA, Veozah, ZEPBOUND, SKYRIZI, ZURZUVAE, AMVUTTRA.
Industry payments across FL — which companies pay providers there.
